Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
European Journal of Nuclear Medicine and Molecular Imaging
Published in: European Journal of Nuclear Medicine and Molecular Imaging 9/2009

01-09-2009 | Original Article

Peptide receptor radionuclide therapy with 90Y-DOTATOC in recurrent meningioma

Authors: Mirco Bartolomei, Lisa Bodei, Concetta De Cicco, Chiara Maria Grana, Marta Cremonesi, Edoardo Botteri, Silvia Melania Baio, Demetrio Aricò, Maddalena Sansovini, Giovanni Paganelli

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 9/2009

Login to get access

Abstract

Purpose

Meningiomas are generally benign and in most cases surgery is curative. However, for high-grade histotypes or partially resected tumours, recurrence is fairly common. External beam radiation therapy (EBRT) is usually given in such cases but is not always effective. We assessed peptide receptor radionuclide therapy (PRRT) using 90Y-DOTATOC in a group of patients with meningioma recurring after standard treatments in all of whom somatostatin receptors were strongly expressed on meningioma cell surfaces.

Methods

Twenty-nine patients with scintigraphically proven somatostatin subtype 2 receptor-positive meningiomas were enrolled: 14 had benign (grade I), 9 had atypical (grade II) and 6 had malignant (grade III) disease. Patients received intravenous 90Y-DOTATOC for 2–6 cycles for a cumulative dose in the range of 5–15 GBq. Clinical and neuroradiological evaluations were performed at baseline, during and after PRRT.

Results

The treatment was well tolerated in all patients. MRI 3 months after treatment completion showed disease stabilization in 19 of 29 patients (66%) and progressive disease in the remaining 10 (34%). Better results were obtained in patients with grade I meningioma than in those with grade II–III, with median time to progression (from beginning PRRT) of 61 months in the low-grade group and 13 months in the high-grade group.

Conclusion

PRRT with 90Y-DOTATOC can interfere with the growth of meningiomas. The adjuvant role of this treatment, soon after surgery, especially in atypical and malignant histotypes, deserves further investigation.
Literature
1.
Black P. Meningiomas. In: Black P, Loeffler JS, editors. Cancer of the nervous system. Oxford UK: Blackwell Science; 1997. p. 349–62.
2.
Russel D, Rubinstein L. Tumours of the meninges and related tissues. In: Russel D, Rubinstein L, editors. Pathology of tumours of the nervous system. Baltimore: Williams and Wilkins; 1989. p. 449–532.
3.
Rachlin J, Rosenblum M. Etiology and biology of meningiomas. In: Al-Mefty O, editor. Meningiomas. New York: Raven; 1991. p. 22–37.
4.
Drake J, Hoffman H. Meningiomas in children. In: Al-Mefty O, editor. Meningiomas. New York: Raven; 1991. p. 145–52.
5.
Butti G, Assietti R, Casalone R, Paoletti P. Multiple meningiomas: a clinical, surgical and cytogenetic analysis. Surg Neurol 1989;31:255–60.PubMedCrossRef
6.
Modan B, Baidatz D, Mart H, Steinitz R, Levin SG. Radiation-induced head and neck tumours. Lancet 1974;1:277–79.PubMedCrossRef
7.
Balasubramaniam C, Armstrong D, Cheek W, Laurent J. Postradiation meningiomas in a child. Pediatr Neurosci 1988;14(3):319–23.PubMedCrossRef
8.
Mark J, Levan G, Mitelman F. Identification by fluorescence of the G chromosome lost in human meningiomas. Hereditas 1972;71:163–8.PubMed
9.
Zankl H, Zang KD. Cytological and cytogenetical studies on brain tumors. 4. Identification of the missing G chromosome in human meningiomas as no. 22 by fluorescence technique. Humangenetik 1972;14(2):167–9.PubMedCrossRef
10.
Kleihues P, Louis DN, Scheithauer BW, Rorke LB, Reifenberger G, Burger PC, et al. The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol 2002;61(3):215–29.PubMed
11.
Simpson D. The recurrence of intracranial meningiomas after surgical treatment. J Neurol Neurosurg Psychiatry 1957;20:22–39.PubMedCrossRef
12.
Marimanoff RO, Dosoretz DE, Linggood RM, Ojemann RG, Martuzza RL. Meningioma: analysis of recurrence and progression after neurosurgical resection. J Neurosurg 1985;62:18–24.CrossRef
13.
Jaaskelainen J, Haltia M, Servo A. Atypical and anaplastic meningiomas: radiology, surgery, radiotherapy, and outcome. Surg Neurol 1986;25:233–42.PubMedCrossRef
14.
Taylor BW Jr, Marcus RB Jr, Friedman WA, Ballinger WE Jr, Million RR. The meningioma controversy: postoperative radiation therapy. Int J Radiat Oncol Biol Phys 1988;15:299–304.PubMedCrossRef
15.
Condra KS, Buatti JM, Mendenhall WM, Friedman WA, Marcus RB Jr, Rhoton AL. Benign meningiomas: primary treatment selection affects survival. Int J Radiat Oncol Biol Phys 1997;39(2):427–36.PubMed
16.
Mesic JB, Hanks GE, Doggett RL. The value of radiation therapy as an adjuvant to surgery in intracranial meningiomas. Am J Clin Oncol 1986;9(4):337–40.PubMedCrossRef
17.
Dziuk TW, Woo S, Butler EB, Thornby J, Grossman R, Dennis WS, et al. Malignant meningioma: an indication for initial aggressive surgery and adjuvant radiotherapy. J Neurooncol 1998;37(2):177–88.PubMedCrossRef
18.
Chan RC, Thompson GB. Morbidity, mortality, and quality of life following surgery for intracranial meningiomas. A retrospective study in 257 cases. J Neurosurg 1984;60:52–60.PubMedCrossRef
19.
Goldsmith BJ, Wara WM, Wilson CB, Larson DA. Postoperative irradiation for subtotally resected meningiomas. A retrospective analysis of 140 patients treated from 1967 to 1990. J Neurosurg 1994;80:195–201. Erratum in: J Neurosurg 1994;80:777.PubMedCrossRef
20.
21.
Pravdenkova S, Al-Mefty O, Sawyer J, Husain M. Progesterone and estrogen receptors: opposing prognostic indicators in meningiomas. J Neurosurg 2006;105(2):163–73.PubMedCrossRef
22.
Black PM. Hormones, radiosurgery and virtual reality: new aspects of meningioma management. Can J Neurol Sci 1997;24(4):302–6.PubMed
23.
Reubi JC, Krenning EP, Lamberts SW, Kvols L. In vitro detection of receptors in human tumours. Digestion 1993;54(Suppl 1):76–83.PubMedCrossRef
24.
De Jong M, Valkema R, Jamar F, Kvols LK, Kwekkeboom DJ, Breeman WA, et al. Somatostatin receptor-targeted radionuclide therapy of tumours: preclinical and clinical findings. Semin Nucl Med 2002;32(2):133–40.PubMedCrossRef
25.
Reubi JC, Maurer R, Klijn JG, Stefanko SZ, Foekens JA, Blaauw G, et al. High incidence of somatostatin receptors in human meningiomas: biochemical characterization. J Clin Endocrinol Metab 1986;63:433–8.PubMedCrossRef
26.
de Herder WW, Kwekkeboom DJ, Valkema R, Feelders RA, van Aken MO, Lamberts SW, et al. Neuroendocrine tumors and somatostatin: imaging techniques. J Endocrinol Invest 2005;28(11 Suppl International):132–6.PubMed
27.
van Essen M, Krenning EP, De Jong M, Valkema R, Kwekkeboom DJ. Peptide receptor radionuclide therapy with radiolabelled somatostatin analogues in patients with somatostatin receptor positive tumours. Acta Oncol 2007;46(6):723–34.PubMedCrossRef
28.
Esser JP, Krenning EP, Teunissen JJ, Kooij PP, van Gameren AL, Bakker WH, et al. Comparison of [(177)Lu-DOTA(0),Tyr(3)]octreotate and [(177)Lu-DOTA(0),Tyr(3)]octreotide: which peptide is preferable for PRRT? Eur J Nucl Med Mol Imaging 2006;33(11):1346–51.PubMedCrossRef
29.
Kwekkeboom DJ, Teunissen JJ, Bakker WH, Kooij PP, de Herder WW, Feelders RA, et al. Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol 2005;23(12):2754–62.PubMedCrossRef
30.
Bodei L, Cremonesi M, Grana C, Rocca P, Bartolomei M, Chinol M, et al. Receptor radionuclide therapy with 90Y-[DOTA]0-Tyr3-octreotide (90Y-DOTATOC) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2004;31(7):1038–46.PubMedCrossRef
31.
Paganelli G, Bodei L, Handkiewicz Junak D, Rocca P, Papi S, Lopera Sierra M, et al. 90Y-DOTA-D-Phe1-Try3-octreotide in therapy of neuroendocrine malignancies. Biopolymers 2002;66(6):393–8.PubMedCrossRef
32.
Paganelli G, Zoboli S, Cremonesi M, Bodei L, Ferrari M, Grana C, et al. Receptor-mediated radiotherapy with 90Y-DOTA-D-Phe1-Tyr3-octreotide. Eur J Nucl Med 2001;28(4):426–34.PubMedCrossRef
33.
Bodei L, Handkiewicz-Junak D, Grana C, Mazzetta C, Rocca P, Bartolomei M, et al. Receptor radionuclide therapy with 90Y-DOTATOC in patients with medullary thyroid carcinomas. Cancer Biother Radiopharm 2004;19(1):65–71.PubMedCrossRef
34.
Chinol M, Bodei L, Cremonesi M, Paganelli G. Receptor-mediated radiotherapy with 90Y-DOTA-DPhe1-Tyr3-octreotide: the experience of the European Institute of Oncology Group. Semin Nucl Med 2002;32(2):141–7.PubMedCrossRef
35.
Bodei L, Cremonesi M, Zoboli S, Grana C, Bartolomei M, Rocca P, et al. Receptor-mediated radionuclide therapy with 90Y-DOTATOC in association with amino acid infusion: a phase I study. Eur J Nucl Med Mol Imaging 2003;30(2):207–16.PubMed
36.
WHO handbook for reporting results of cancer treatment. Geneva, Switzerland: World Health Organization Offset Publication; 1979. p. 48.
37.
Green S, Weiss GR. Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria. Invest New Drugs 1992;10:239–53.PubMedCrossRef
38.
Grunberg SM, Weiss MH, Spitz IM, Ahmadi J, Sadun A, Russell CA, et al. Treatment of unresectable meningiomas with the antiprogesterone agent mifepristone. J Neurosurg 1991;74(6):861–6.PubMedCrossRef
39.
Grumberg SM, Rankin C, Townsend J, Ahmadi J, Feun L, Fredericks R, et al. Phase III double-blind randomized placebo controlled study of mifepristone (RU) for the treatment of unresectable meningioma. ASCO 2001 Proceedings 20:56a.
40.
Klutmann S, Bohuslavizki KH, Brenner W, Behnke A, Tietje N, Kröger S, et al. Somatostatin receptor scintigraphy in postsurgical follow-up examinations of meningioma. J Nucl Med 1998;39:1913–17.PubMed
41.
Henze M, Dimitrakopoulou-Strauss A, Milker-Zabel S, Schuhmacher J, Strauss LG, Doll J, et al. Characterization of 68Ga-DOTA-D-Phe1-Tyr3-octreotide kinetics in patients with meningiomas. J Nucl Med 2005;46(5):763–9.PubMed
42.
Gay E, Vuillez JP, Palombi O, Brard PY, Bessou P, Passagia JG. Intraoperative and postoperative gamma detection of somatostatin receptors in bone-invasive en plaque meningiomas. Neurosurgery 2005;57(1 Suppl):107–13.PubMedCrossRef
43.
Chamberlain MC, Glantz MJ, Fadul CE. Recurrent meningioma: salvage therapy with long-acting somatostatin analogue. Neurology 2007;69(10):969–73.PubMedCrossRef
44.
Koper JW, Markstein R, Kohler C, Kwekkeboon DJ, Avezaat CJ, Lamberts SW, et al. Somatostatin inhibits the activity of adenylate cyclase in cultured human meningioma cells and stimulates their growth. J Clin Endocrinol Metab 1992;74(3):543–7.PubMedCrossRef
45.
Ko KW, Nam DH, Kong DS, Lee JI, Park K, Kim JH. Relationship between malignant subtypes of meningioma and clinical outcome. J Clin Neurosci 2007;14(8):747–53.PubMedCrossRef
46.
Modha A, Gutin PH. Diagnosis and treatment of atypical and anaplastic meningiomas: a review. Neurosurgery 2005;57(3):538–50.PubMedCrossRef
47.
Ho DM, Hsu CY, Ting LT, Chiang H. Histopathology and MIB-1 labeling index predicted recurrence of meningiomas: a proposal of diagnostic criteria for patients with atypical meningioma. Cancer 2002;94(5):1538–47.PubMedCrossRef
48.
Brans B, Bodei L, Giammarile F, Linden O, Luster M, Oyen WJ, Tennvall J. Clinical radionuclide therapy dosimetry: the quest for the "Holy Gray". Eur J Nucl Med Mol Imaging 2007;34(5):772–86.PubMedCrossRef
49.
Cremonesi M, Ferrari M, Bodei L, Tosi G, Paganelli G. Dosimetry in peptide radionuclide receptor therapy: a review. J Nucl Med 2006;47(9):1467–75.PubMed
50.
van Essen M, Krenning EP, Kooij PP, Bakker WH, Feelders RA, de Herder WW, et al. Effects of therapy with [177Lu-DOTA0, Tyr3]octreotate in patients with paraganglioma, meningioma, small cell lung carcinoma, and melanoma. J Nucl Med 2006;47(10):1599–606.PubMed
Metadata
Title
Peptide receptor radionuclide therapy with 90Y-DOTATOC in recurrent meningioma
Authors
Mirco Bartolomei
Lisa Bodei
Concetta De Cicco
Chiara Maria Grana
Marta Cremonesi
Edoardo Botteri
Silvia Melania Baio
Demetrio Aricò
Maddalena Sansovini
Giovanni Paganelli
Publication date
01-09-2009
Publisher
Springer-Verlag
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 9/2009
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-009-1115-z

Other articles of this Issue 9/2009

European Journal of Nuclear Medicine and Molecular Imaging 9/2009 Go to the issue

Original Article

In vitro characterization of 177Lu-radiolabelled chimeric anti-CD20 monoclonal antibody and a preliminary dosimetry study

Editorial

99Mo supply—the times they are a-changing

Original Article

Validation of sentinel lymph node dissection in prostate cancer: experience in more than 2,000 patients

Editorial

Darwinian molecular imaging

Original Article

188Re-HEDP combined with capecitabine in hormone-refractory prostate cancer patients with bone metastases: a phase I safety and toxicity study

Original Article

Staging primary head and neck cancers with 18F-FDG PET/CT: is intravenous contrast administration really necessary?